AXL inhibition as a novel treatment of aggressive disease Short presentations will be given by our investigators and AXL KOLs in a relaxed atmosphere. Presentations will be made available in the investors section following the event. For further details and to receive an invitation please contact: priya.nanduri@bergenbio.com ASCO Personal Invitation